Navigation Links
NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
Date:11/4/2010

PARK CITY, Utah, Nov. 4, 2010 /PRNewswire/ -- NuView Life Sciences, Inc ("NuView"), a biopharmaceutical company specializing in the development of proprietary target specific biomarkers for utilization with Positron Emission Tomography ("PET") imaging procedures, announced today that its applications for the Qualifying Therapeutic Discovery Project Credit ("Therapeutic Credit") were approved.

The grants totaling just over $1.2 million dollars were awarded to NuView for further development and validation of several of the Company's projects. The diagnostic imaging biomarker projects that were approved under the Therapeutic Credit program are for breast cancer, lymphoma, cancer proliferation and cardiovascular imaging.

"We are very pleased that the underlying science of our pipeline candidates has been recognized under the Therapeutic Credit program, further enabling the clinical advancement of these projects," commented Paul Crowe, Chairman and Chief Executive Officer of NuView.

About the Qualifying Therapeutic Discovery ProjectThe Qualifying Therapeutic Discovery Project tax credit or grant is provided under new section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). The tax credit or grant is a benefit targeted to therapeutic discovery projects that show a reasonable potential to:

  • Result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions;
  • Reduce the long-term growth of health care costs in the United States, or significantly advance the goal of curing cancer within 30 years.

  • Allocation of the credit or grant also takes into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences. The credit or grant is only available to companies with no more than 250 employees. The total amount of credits available to all companies is limited to $1 billion.

    About NuView Life Sciences, IncNuView Life Sciences, Inc is a privately held Utah based biopharmaceutical company developing target specific biomarkers for diagnostic Positron Emission Tomography ("PET") imaging procedures. The Company's clinical stage pipeline includes several proprietary products for diagnosing cancer and heart disease.  Please visit our website at www.nuviewinfo.com.For more information please contact:

    Rob Alday NuView Life Sciences, IncTel.  435-647-9758Fax. 435-647-5602info@nuviewinfo.com
    '/>"/>

    SOURCE NuView Life Sciences, Inc
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
    2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
    3. Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions
    4. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
    5. Pittsburgh Life Sciences Greenhouse and Innovation Works Announce Investments in Ib2C™
    6. Indiana Life Sciences Start Ups Garner More than $1.5 Million in Competitive Federal Funding
    7. Neurocrine Biosciences Reports Third Quarter 2010 Results
    8. Neurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    9. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
    10. Caliper Life Sciences Signs Co-Marketing Pact with Illumina to Improve Sequencing Workflows
    11. Caliper Life Sciences Expands Offering for Next Generation Sequencing Workflows
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/7/2016)... 2016   Arena Pharmaceuticals, Inc. (NASDAQ: ... enrollment in the ralinepag phase 2 trial.  Ralinepag is ... pathway for the treatment of pulmonary arterial hypertension (PAH). ... "This marks an important step in the ... focus on our pipeline," said Amit Munshi , ...
    (Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
    (Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
    Breaking Medicine Technology:
    (Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
    (Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
    (Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic and ... website, which launched October 17, 2016, features comprehensive information regarding a wide range ... Visitors and patients can discover the latest clinical dermatology treatments for medical skin ...
    (Date:12/7/2016)... ... , ... The medical profession is well aware that heart attacks do indeed ... heart attacks among 138,602 people recorded a 35% higher number of heart attacks in ... of course–no time of year is a good time for a heart attack! In ...
    (Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
    Breaking Medicine News(10 mins):